|
Market Closed -
Nasdaq
04:00:00 2026-01-15 pm EST
|
5-day change
|
1st Jan Change
|
|
44.00 USD
|
-4.95%
|
 |
+21.53%
|
+293.08%
|
|
23-09-11 |
Adrenoleukodystrophy Clinical Trials, and Key Companies|Companies - Bluebird Bio, Minoryx Therapeutics, MedDay Pharmaceuticals, Magenta Therapeutics, Orpheris Inc, SOM Biotech, and many others
|
AQ
| |
23-08-07 |
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
|
BU
| |
23-05-03 |
Shareholder Alert: Ademi LLP investigates whether Magenta Therapeutics, Inc. has obtained a Fair Price in its transaction with Dianthus
|
PR
| |
23-05-03 |
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
|
BU
| |
23-05-03 |
MGTA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Magenta Therapeutics, Inc. Is Fair to Shareholders
|
BU
| |
23-05-03 |
MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
|
AQ
| |
23-05-03 |
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement
|
AQ
| |
23-04-06 |
MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement (form 8-K)
|
AQ
| |
23-03-31 |
MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
|
AQ
| |
23-03-31 |
Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan
|
AQ
| |
23-03-23 |
MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS (form 10-K)
|
AQ
| |
23-02-07 |
MAGENTA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers (form 8-K)
|
AQ
| |
23-02-02 |
MAGENTA THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
|
AQ
| |
23-02-02 |
Magenta Therapeutics to Explore Strategic Alternatives
|
AQ
| |
23-01-25 |
MAGENTA THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
|
AQ
| |
23-01-25 |
Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety
|
AQ
| |
22-12-20 |
MAGENTA THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
|
AQ
| |
22-12-20 |
Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial
|
AQ
| |
22-12-13 |
Magenta Therapeutics : Update on MGTA-117 Presentation
|
PU
| |
22-12-13 |
MAGENTA THERAPEUTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
|
AQ
| |
22-12-12 |
Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates
|
AQ
| |
22-12-12 |
Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial
|
AQ
| |
22-11-03 |
MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS. (form 10-Q)
|
AQ
| |
22-11-03 |
MAGENTA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
|
AQ
| |
22-11-03 |
Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights
|
AQ
|
No results for this search Select your edition All financial news and data tailored to specific country editions | 
